Syneos Health and Aetion Partner to Offer RWE Solutions to Advance Drug Development and Commercialization
August 02, 2021 07:00 ET
|
Syneos Health, Inc.
MORRISVILLE, N.C. and NEW YORK, Aug. 02, 2021 (GLOBE NEWSWIRE) -- Syneos Health® (Nasdaq:SYNH) and Aetion® announced a partnership to provide regulatory-grade data and analytics-driven solutions to...
XBiotech Announces Payment of Dividend to Holders of Common Stock
July 30, 2021 11:03 ET
|
XBiotech Inc.
AUSTIN, Texas, July 30, 2021 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT) (“XBiotech”) has completed payment to holders of its Common Stock of a previously announced dividend in the amount of...
2021 Outlook on Decentralized Clinical Trials - Cloud-based Platform to Achieve Scalability and Workflow Standardization Presents Opportunities
July 26, 2021 06:23 ET
|
Research and Markets
Dublin, July 26, 2021 (GLOBE NEWSWIRE) -- The "Global Decentralized Clinical Trial (DCT) Growth Opportunities" report has been added to ResearchAndMarkets.com's offering. The report presents...
Global Clinical Trial Market (2020 to 2026) - Featuring ICON, Wuxi AppTec and SGS Among Others
July 22, 2021 08:03 ET
|
Research and Markets
Dublin, July 22, 2021 (GLOBE NEWSWIRE) -- The "Clinical Trial Market, Global Forecast Impact of COVID-19, Industry Trends by Phases, Study Design, Region, Opportunity Company Overview, Revenue"...
Ivy Brain Tumor Center Announces Plan to Build New Global Headquarters in Phoenix
July 21, 2021 05:00 ET
|
Ivy Brain Tumor Center
Phoenix, AZ, July 21, 2021 (GLOBE NEWSWIRE) -- The Ivy Brain Tumor Center at Barrow Neurological Institute, the largest Phase 0 clinical trials program for aggressive brain tumors, announced its...
Fluidigm Announces Conference Call and Webcast of Second Quarter 2021 Financial Results
July 08, 2021 16:01 ET
|
Fluidigm Corporation
SOUTH SAN FRANCISCO, Calif., July 08, 2021 (GLOBE NEWSWIRE) -- Fluidigm Corporation (Nasdaq:FLDM), an innovative biotechnology tools provider with a vision to improve life through comprehensive...
XBiotech Announces Dividend to Holders of Common Stock
July 06, 2021 16:30 ET
|
XBiotech Inc.
AUSTIN, Texas, July 06, 2021 (GLOBE NEWSWIRE) -- XBiotech Inc.’s (NASDAQ: XBIT) (“XBiotech”) Board of Directors has declared an extraordinary cash dividend of approximately $2.50 per share, or up to...
XBiotech Announces Receipt of $75 Million from Sale of Antibody
June 30, 2021 11:46 ET
|
XBiotech Inc.
AUSTIN, Texas, June 30, 2021 (GLOBE NEWSWIRE) -- XBiotech (NASDAQ: XBIT) announced today it received $75 million from funds escrowed as part of its December 2019 sale of bermekimab. The True Human™...
vTv Therapeutics to Participate at the 6th World Psoriasis & Psoriatic Arthritis Conference with Poster Presentation on HPP737
June 29, 2021 07:30 ET
|
vTv Therapeutics Inc.
HIGH POINT, N.C., June 29, 2021 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT) a clinical-stage biopharmaceutical company focused on the development of orally administered treatments for...
XBiotech Announces First Patient Enrolled in Clinical Trial Evaluating XB2001 for the Treatment of Pancreatic Cancer
June 23, 2021 08:30 ET
|
XBiotech Inc.
AUSTIN, Texas, June 23, 2021 (GLOBE NEWSWIRE) -- XBiotech Inc. (NASDAQ: XBIT) has enrolled the first patient in its 1-BETTER study, a randomized, double-blind, placebo-controlled clinical study to...